dp-b99 and Nervous-System-Diseases

dp-b99 has been researched along with Nervous-System-Diseases* in 1 studies

Reviews

1 review(s) available for dp-b99 and Nervous-System-Diseases

Article	Year
DP-b99 (D-Pharm). Current opinion in investigational drugs (London, England : 2000), 2004, Volume: 5, Issue:1 DP-b99 is a derivative of the calcium chelator BAPTA that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and neurological damage associated with coronary artery bypass graft. By March 2003, phase II clinical trials in acute stroke and traumatic brain injury were ongoing. Topics: Animals; Brain Ischemia; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Coronary Artery Bypass; Craniocerebral Trauma; Egtazic Acid; Humans; Nervous System Diseases; Neuroprotective Agents; Structure-Activity Relationship	2004

Article

Year

Current opinion in investigational drugs (London, England : 2000), 2004, Volume: 5, Issue:1

DP-b99 is a derivative of the calcium chelator BAPTA that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and neurological damage associated with coronary artery bypass graft. By March 2003, phase II clinical trials in acute stroke and traumatic brain injury were ongoing.

Topics: Animals; Brain Ischemia; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Coronary Artery Bypass; Craniocerebral Trauma; Egtazic Acid; Humans; Nervous System Diseases; Neuroprotective Agents; Structure-Activity Relationship

2004